Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|October 27, 2020

Naloxone and Combatting the Rising Opioid Fatalities

Author(s)Nishi Rawat, MD, MBA

The reported increase in opioid related overdoses, likely fed by the disturbances of COVID-19, necessitates a need for more widely-accessible Naloxone, an emergency life-saving treatment.

Dr Rawat is a co-founder of OpenBeds and Senior Vice President at Appriss Health. She is a physician and healthcare services researcher, trained in Critical Care and Emergency Medicine, and faculty at Johns Hopkins University School of Medicine.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Giama22/Adobe Stock

Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence

ByJoseph F. Goldberg, MD,Carl Salzman, MD

August 12th 2026

TensorSpark/Adobe Stock

Psyched Perspectives: Substance Use Awareness, A Conversation on Advocacy & Intervention

ByFrank A. Clark, MD,Chelby Drafts

July 31st 2026

Virtual Gambling Disorder Treatment Shows Rapid Symptom Improvement in New Study

Virtual Gambling Disorder Treatment Shows Rapid Symptom Improvement in New Study

ByPatrick Campbell

July 31st 2026

drugs alcohol

Podcast: Managing Co-Occurring Mood and Substance Use Disorders With Michael J. Ostacher, MD, MPH

ByJoseph F. Goldberg, MD,Michael J. Ostacher, MD, MPH

July 17th 2026

Developments in Cannabis Withdrawal and Addiction Treatment

ByGinger Constantine, MD

July 8th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

New Ingrezza Data Shows Improved Quality of Life and Daily Functioning in Tardive Dyskinesia

Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence